A single-session gain of 64% on the first day we placed DCTH on our watchlist is certainly nothing to sneeze at, and given the circumstances behind the upward surge, that may have only been the beginning.
The company received word from the FDA that its Primary Liver Disease treatment, ChemoSat, had received “orphan drug” designation, a classification which denotes a drug or procedure that is aimed at a disease which affects less than 200,000 people. About 26,000 Americans are diagnosed with Primary Liver Disease each year.
(Thomson Reuters ONE via COMTEX) — New York, NY – October 1, 2013 – Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology, announced today that the U.S. Food & Drug Administration (FDA) has granted the Company orphan drug designation for melphalan in the treatment of patients with hepatocellular carcinoma (HCC, or primary liver cancer). >>>FULL STORY
Side Note:
We rarely see stocks in this price range with an active options chain, but DCTH is an exception. The 12/21 .50 Calls jump out at us at first glance. If the stock were to approach a dollar between now and the expiration date, one could be looking at triple-digit gains.
Zalicus, Inc. ZLCS
Coincidentally, ZLCS, a stock that we’ve been following since the beginning of last month, also received a recent FDA orphan drug designation for its experimental Z160 drug, intended for the treatment of pain related to the Shingles.
Hitting a high of 1.38 yesterday, we finally saw ZLCS fill the gap on the chart that we had been pointing out for some time. Since we’ve been following ZLCS, we’ve seen a low of .78, and yesterday’s high represents a 77% gain off of that bottom. The filling of that gap was a pretty good indicator that it was time to take profits off of the table, so we certainly hope that folks were able to take advantage.
This morning, they also announced a reverse split, the result of which should be the stocks continued listing on the Nasdaq Capital Market, as it should enable shares to remain above the 1.00 minimum bid price required for listing. We would expect shares to come away from this split valued in the $6.00-range, and sure enough, we are seeing trades go off as high as 6.45 pre-market.
Zalicus Inc. (Nasdaq Capital Market: ZLCS) today announced that it has filed a Certificate of Amendment to its Sixth Amended and Restated Certificate of Incorporation, with the Secretary of State of the State of Delaware to effect a 1-for-6 reverse stock split of Zalicus common stock, effective as of October 3, 2013 at 12:01 a.m. Eastern Time…The reverse stock split will reduce the number of shares of common stock issued and outstanding from approximately 147.5 million to approximately 24.6 million. >>> FULL STORY
Extended Watchlist:
